MEK1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09226(ZNF19 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P09226(ZNF19 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

MEK1 (Mitogen-Activated Protein Kinase Kinase 1), also known as MAP2K1. is a central component of the RAS/RAF/MEK/ERK signaling pathway, which regulates critical cellular processes including proliferation, differentiation, survival, and apoptosis. As a dual-specificity kinase, MEK1 phosphorylates and activates ERK1/2 (Extracellular Signal-Regulated Kinases 1 and 2), which subsequently translocate to the nucleus to modulate gene expression. Dysregulation of this pathway, often due to mutations in MEK1 or upstream regulators like RAS and RAF, is implicated in various cancers, inflammatory diseases, and developmental disorders. For example, activating MEK1 mutations (e.g., P124S, Q56P) are found in melanoma, lung adenocarcinoma, and cardio-facio-cutaneous syndrome.

MEK1 antibodies are essential tools in biomedical research for detecting and quantifying MEK1 protein expression, phosphorylation status, and localization in cells or tissues. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Phospho-specific MEK1 antibodies, which recognize activated forms (e.g., phosphorylated at Ser217/221), help assess pathway activity in response to stimuli or therapeutic interventions. The development of selective MEK1 antibodies has also supported the study of MEK inhibitors (e.g., trametinib, cobimetinib) in cancer therapy and resistance mechanisms. Researchers rely on these antibodies to validate MEK1 expression in disease models, monitor drug efficacy, and explore MEK1's role in signaling crosstalk. Ensuring antibody specificity through validation (e.g., knockout controls) is critical to avoid cross-reactivity with homologous proteins like MEK2.